FrontPage is India's Stock Market Social Network
Join 3,00,000+ Traders and Investors
NOVARTIND
601234567897012345678980123456789.7012345678950123456789
+6.80 (+1.01%)
Previous Close: 671.95
1D
5D
1M
3M
1Y
5Y
NewsBot-display-image
Reputation: 27,802  •  Aug 25 4:31 AM
Novartis to spin off generics biz sandoz
The company started a strategic review of Sandoz last October - examining a range of options, including retaining the business, spinning it off or selling it - following a protracted period of underperformance driven largely by mounting pricing pressures in the off-patent drug sector.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Aug 25 4:16 AM
Swiss drugmaker Novartis to spin off generics unit Sandoz
The Basel-based company, which makes a vast array of drugs including cancer treatment Gleevec and Diovan for hypertension, says it wants to focus on its core innovation business that is built around therapeutics and technology such as gene and cell therapy.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Aug 25 6:56 AM
Energy stocks boost European shares ahead of ECB minutes; DAX jumps after GDP data
Novartis rose 0.8% after saying it would spin off Sandoz and list the biosimilars unit on the Swiss stock exchange to create the No.1 European generics company and a more focused parent group.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Aug 25 11:21 AM
Torrent Pharma set to acquire Curatio
The transaction will see the exit of existing investors of Curatio, such as ChrysCapital (which holds a 20% stake) and Sequoia Capital (33%). Promoters, including GK Ramani, and the management will also be exiting the company.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Aug 25 5:41 AM
Eris Lifesciences Scouting for Acquisitions to Diversify Biz
Through acquisition of Strides domestic formulations portfolio in 2017, Eris Lifesciences got a toehold in the neurology and psychiatry segments, followed by another acquisition in 2019 of anti-diabetes brand Zomelis, generic version of Vildagliptin, from Novartis, which became a ₹100 crore brand for the company. Earlier this year, the company bought Oaknet for ₹650 crore. Eris Lifesciences ended 2021-22 with revenues of ₹1,347 crore, with 53% contributed by cardiology and anti-diabetes medications.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Aug 18 5:56 AM
Anil Matai, Vijender Singh join Jashvik Capital
Vijender Singh was most recently CEO of Metropolis Healthcare and COO of Dr. Lals Pathlabs, where Vijender helped scale both these companies under private equity ownership.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jul 26 3:01 AM
Edelweiss Securities leases 1 lakh sq ft in Adani Realty’s office tower in Mumbai’s BKC
The firm is expected to pay total rentals worth over Rs 285 crore over the tenure of the lease based on monthly rentals of Rs 220 per sq ft, including common area maintenance charges. The agreement includes a rent escalation clause with 15% upward revision every three years. The deal is structured with a lock-in period of three years.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jul 1 5:21 AM
JB Pharma acquires paediatric brands from Dr Reddy's for Rs 98.3 crore
The four brands are zinc supplement Z&D, insomnia medication Pedicloryl, antibiotic Pecef and Ezinapi, which is used against diaper rashes. The four brands combined had sales of Rs 33 crore in the fiscal year ended March 31, 2022.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jun 30 4:21 AM
Novartis opens new manufacturing plant in Mumbai to make generic cancer drugs
Spread across 32,000 sqm, and housing state-of-the-art production technology, the plant is built to cater to export markets. It currently has a workforce of 70 people with plans to increase further to support the expansion of production capacity and capabilities.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jun 28 2:56 AM
Novartis to cut up to 8,000 jobs globally
Novartis said in an emailed statement it had made good progress in implementing its new organisational structure that involved integrating its pharmaceuticals and oncology business units and would lead to eliminating roles across the organisation.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jun 13 6:51 AM
Vahdam India appoints Sneha Beriwal as CMO
Sneha brings in over 17 years of experience and prior to joining Vahdam, she worked at Aditya Birla Group for 5 years where she started as AVP - Marketing at Aditya Birla Payments Bank, and then became the Head - Brand & Campaigns at Aditya Birla Fashion and Retail Ltd - Pantaloons and in 2022, she served as Joint Vice-President, Marketing at Aditya Birla Health Insurance Company Limited.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jun 6 10:36 AM
It's a challenging time for start-ups. But Snapdeal boss sees a silver lining, says it was much-needed
Kunal Bahl said that many founders are helping their peers with network & unused laptops.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  May 31 6:11 AM
Bayer's consumer health unit plans to step up India play
In an interview to ET, Sandeep Verma, country head, India, Bayer consumer health division in India, said the company will use its global expertise to launch new formats such as effervescent tablets, topicals and sprays and expand its distribution footprint from 5.5 lakh pharmacies to 10 lakh by 2026, besides launching marketing campaigns to energize the brands.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  May 27 1:26 AM
KKR-backed JBCPL unveils new logo & identity
“In 45 years, we at JB have built a strong foundation of integrity, trust and reliability. Now we are taking the next leap forward towards becoming more agile, lean and simple," said Nikhil Chopra, CEO & whole-time director of JB.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  May 20 4:56 AM
Sensex rises! But these stocks are down 5% or more on BSE
In the Nifty pack, 48 stocks were trading in the green, while 1 stocks were trading in the red.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  May 20 4:46 AM
Sensex rises! These stocks are up over 10% on BSE
In the Nifty 50 index, 48 stocks were trading in the green, while 1 stocks were trading in the red.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  May 17 3:46 AM
Global Capacity Centres in India to add 200,000 jobs in FY22
Companies on top of the hiring action include Amex, Bank of America, Wells Fargo, Citi, Barclays, Morgan Stanley, HSBC, Standard Chartered, Goldman Sachs, Amazon, Target, Walmart, Shell, GSK, Abbott, Pfizer, J&J, Novartis, and AstraZeneca, among others, according to Xpheno data.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Apr 26 8:31 AM
European stocks bounce back on earnings support
The continent-wide STOXX 600 rose 0.6% after plunging nearly 2% on Monday on worries of an economic slowdown in China and rapid U.S. interest rate hikes.
The Economic Times
Like
Comment
Share
Add a comment
ResultsBot-display-image
Reputation: 20,221  •  Feb 8 12:30 PM

#NOVARTIND will declare results on Feb 10, 2022
Do you have any view on the results? Let's aggregate whatever information we have from other sources for everyone's benefit.
Like
Comment
Share
Add a comment
Equity And Option Trader-display-image
Reputation: 37,391  •  Jan 23 12:16 PM
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Nov 19, 2021 8:36 AM
Laurus Labs acquires stake in IIT-Bombay incubated CAR-T cell therapy company
As per the agreement, Laurus will acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs 46 crores, subject to the fulfilment of certain conditions.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Nov 10, 2021 10:51 AM
Biggest gainers & losers of the day: Nykaa's stellar debut, BHEL tanks
Nykaa shares extended their rally during the day and settled at Rs 2208.35, 96 per cent over its issue price of Rs 1,125 per share.
The Economic Times
Like
Comment
Share
Add a comment
ResultsBot-display-image
Reputation: 20,221  •  Nov 9, 2021 12:30 PM

#NOVARTIND will declare results on Nov 11, 2021
Do you have any view on the results? Let's aggregate whatever information we have from other sources for everyone's benefit.
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Nov 5, 2021 7:16 AM
Roche says controlling family won't have to make offer to other shareholders
The pool of family shareholders, who previously owned 45.01% of the voting rights in Roche, were given the exemption by the Swiss takeover board, the company said.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Oct 26, 2021 7:26 AM
Upbeat earnings pull European stocks higher; Reckitt gains on forecast lift
The financial services sector rose about 1% as the world's largest wealth manager, UBS, gained 2.4% after posting its best quarterly profit since 2015, helped by robust trading activity.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Oct 5, 2021 1:31 AM
WHO's Solidarity clinical trials: India to start trials of two new drugs to treat Covid-19
India is among the 52 countries taking part in WHO's Solidarity PLUS trial. This collaboration for Covid-19 research is also studying the effectiveness of another drug - Artesunate, which is used for treatment of severe malaria. The trials in some other countries will include this third drug.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Oct 4, 2021 9:36 AM
What if we told you there are courses in Ireland that guarantee you jobs?
In terms of post-study work opportunities for graduates, following Brexit, Ireland is now the only majority English-speaking country in the European Union. This means that Ireland provides the benefits of an English-speaking education in a country that is Europes economic and technological centre.
The Economic Times
Like
Comment
Share
Add a comment
Money Masterji-display-image
Reputation: 363  •  Oct 4, 2021 3:12 AM

INTRADAY BUY NOVARTIS ABOVE 824, TGT 830/836, SL 818
1 Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Aug 12, 2021 6:06 AM
Novartis India Q1 net profit rises 43% to Rs 6 crore
Revenue from operations stood at Rs 98.11 crore for the quarter under consideration. It was Rs 92.46 crore for the same period a year ago, it added.
The Economic Times
Like
Comment
Share
Add a comment
ResultsBot-display-image
Reputation: 20,221  •  Aug 9, 2021 12:30 PM

#NOVARTIND will declare results on Aug 11, 2021
Do you have any view on the results? Let's aggregate whatever information we have from other sources for everyone's benefit.
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Aug 9, 2021 7:51 AM
Zydus Cadila likely to get emergency use approval for its COVID vaccine this week: Sources
Zydus Cadila last month had said that it has applied for emergency use authorisation (EUA) with the Indian Drug regulator for its three-dose COVID-19 vaccine ZyCoV-D, and plans to manufacture 10-12 crore doses annually.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jul 21, 2021 7:56 AM
Blue-chip earnings, travel stocks boost European shares
The pan-European STOXX 600 index rose 1.4%, extending Tuesday's small gains. Travel and leisure stocks jumped 4.2% after getting hammered recently by worries about a resurgence in virus cases.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jul 21, 2021 5:51 AM
Novartis set to deliver 50 mn CureVac COVID-19 vaccines this year
"We have started the production as planned. We are planning to deliver 50 million doses this year," Kirsch said of the CureVac deal when asked whether it could instead make its capacity free for others after CureVac said last month its COVID-19 jab was only 48% effective.
The Economic Times
1 Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jun 17, 2021 12:51 PM
Novartis India Q4 results: Net profit rises 43% to Rs 10 cr
Revenue from operations stood at Rs 99.29 crore as compared to Rs 93.7 crore in the year-ago quarter.
The Economic Times
Like
Comment
Share
Add a comment
Neeraj Puri Goswami-display-image
Reputation: 10,308  •  Jun 14, 2021 6:24 AM
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  May 6, 2021 5:21 AM
Medical companies seek G-20 protection for patents
The warning comes in a report prepared for G-20 leaders by representatives of health and life-sciences companies including Novartis AG, Sanofi FP, AstraZeneca and Johnson & Johnson, and from organisations such as the OECD and Europes EFPIA pharmaceutical industry association.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Apr 29, 2021 1:51 AM
Roche to boost Tocilizumab supply to meet rising demand in India
The cost of the drug in India is upwards of ₹50,000 per vial. However, due to shortage the drug has been selling at exorbitant prices according to people trying to procure the drug.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Mar 30, 2021 4:06 AM
BioNTech-Pfizer raise 2021 vaccine output goal to 2.5 billion doses
Pfizer previously said the partners would likely produce between 2.3 billion and 2.4 billion doses in 2021. BioNTech cited its new facility in the German city of Marburg and an expansion of the pair's network of third-party manufacturers and suppliers as drivers of the larger volumes.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Mar 30, 2021 4:46 AM
Stock market update: 23 stocks hit 52-week lows on NSE
In the Nifty 50 index, UPL , JSW Steel, Tata Steel, Shree Cements and NTPC were among the top gainers on the NSE.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Jan 26, 2021 9:11 AM
European shares rebound on gains in chemical, financial sectors
The pan-European STOXX 600 index rose 0.8%, with the German DAX gaining 1.5%, Frances CAC 40 up 1.1% and UKs FTSE 100 adding 0.7%.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Dec 17, 2020 5:56 AM
Novartis to buy neuroscience company Cadent for up to $770 million
Novartis said on Thursday it had entered into an agreement to acquire U.S.-based neuroscience company Cadent for up to $770 million, gaining full rights to Cadent's neuroscience portfolio.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Dec 14, 2020 10:31 AM
MNC pharma lobby pushes for single drug authority here
The OPPI, which represents 22 pharma companies, including Abbott, Pfizer, Novartis, Novo Nordisk and Sanofi, also wants specialised patent courts for fast disposal of patents and IP disputes.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Dec 10, 2020 1:31 AM
Luxembourg’s B Medical systems in talks with all top Covid vaccine makers for refrigeration unit in India
A delegation of B Medical executives, which is currently in India, held meetings with India's principal scientific adviser and officials at the Ministry External Affairs on the proposed unit and the companys technology, and claimed to have received strong support from them.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 27,802  •  Nov 26, 2020 2:31 AM
Infectious diseases' drug research back on the radar of Big Pharma
Companies such as Gilead, Eli Lilly and Regeneron have worked on novel treatments, either from their own labs or by reviving molecules that had been abandoned during other epidemics. For example, Gileads Remdesivir was originally tried as a cure for Ebola. Companies such as Eli Lilly and Regeneron have revived the field of antibody therapy that has become a key foundation for Covid-19 treatments.
The Economic Times
Like
Comment
Share
Add a comment